- Avita Medical Ltd. ADR (OTCQX:AVMXY): Q2 Revenue of A$3.9M (+65.3% Y/Y)
- Press Release
- More news on: Avita Medical Ltd. ADR, Earnings news and commentary, Healthcare stocks news, ,
home / stock / avmxy / avmxy news
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, annou...
Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the he...
First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of...